The company is led by Robert Whitehead, a seasoned pharma executive with a strong history of creating value for investors, including previous strategic exits that yielded 11x and 18x returns. In June 2024, Continuity partnered with Dr. Alessandro Grattoni, a leader in nanomedicine, to acquire rights to NICHE drug delivery technologies. Dr. Grattoni’s research aims to develop implantable nanofluidic systems for controlled therapeutic release, supported by approximately $40 million in research funding from various sources.

Continuity is assembling a skilled team of pharmaceutical executives experienced in drug development and strategic partnerships. The company’s board and advisory groups include international business and healthcare management experts. Active discussions for pharmaceutical partnerships are underway, positioning Continuity to leverage its expertise and innovative technologies in the biopharmaceutical market.